The goal of this study is to test if the study drug, OP-1250, is better or worse than the usual approach for your type of breast cancer. The usual approach, also known as the “standard of care”, is defined as care most people get for ER+, HER2- advanced or metastatic breast cancer. In this study we will compare OP-1250 with standard endocrine therapies for this disease such as fulvestrant, anastrozole, letrozole, or exemestane.